A phase II trial of ImmunotheRapy with single fRactIon non-ablative raDIAtion in previously untreated patients with stage IV NSCLC. (IRRIDIATE-Lung trial).

Brief description of study

You can participate in this study if you are diagnosed with advanced lung cancer. The primary goal of this trial is to evaluate the efficacy of focal radiation to index lesions as a way of enhancing the anti-tumor immune response to study drug (pembrolizumab).

This study also determines the safety and toxicity of the combination of radiation and study drug (pembrolizumabz). The patients will be monitored and taken care of while on this medication and radiation therapy during the entire study period.


Clinical Study Identifier: s22-00673
ClinicalTrials.gov Identifier: NCT05691829
Principal Investigator: Vamsidhar Velcheti.
Other Investigators: Gerard Donnelly, Marta Wioleta Wronska, Elaine Shum, David Mendoza, Anna Kurzyna-Solinas, Joshua S. Silverman, Francis Arena, Alma Nesimi, Danny Perlaza, Jessica Wang, Joshua K Sabari, Todd J Carpenter, Marissa Rybstein, Natalia Cherkassky, Benjamin Cooper, Avital Benson, Jagdeep Raince, Abraham Chachoua, Elka R Travis, Salman Rafi Punekar, Sally Lau, Jeffrey G Schneider, Samantha VanMaanen, Thomas B. Daniels, Judith D Goldberg, James Newman, Melissa L Martinez, Jonathan W Lischalk, Moses M Tam, David Jaihun Byun.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.